Niagen Bioscience Inc. Common Stock (NAGE)

FairStock Score: 49/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Niagen and see a small bioscience company selling NAD+ and healthy-aging supplements through consumer, ingredient, and pharmaceutical segments. The story has improved: FY2023 revenue was $83.6M with a $4.9M net loss; FY2024 revenue was $99.6M with $8.6M net income; and FY2025 revenue was $129.4M with $17.4M net income, or $0.20 diluted EPS. That fits the computed Lynch category of turnaround. The balance sheet is conservative: debt-to-equity is 0.03, Altman Z-Score is 4.26, Piotroski F-Score is 8/9, and trailing free cash flow is $5.7M, a 2.8% FCF yield. But the recent trend is troubling. In fiscal Q1 2026, revenue was $31.5M and net income $6.3M; in fiscal Q2 2026, revenue fell to $29.8M and net income to just $963,000, or $0.01 diluted EPS. Overall revenue growth is -4.28% and profit growth is -73.32%, so the turnaround has stalled. Valuation is not compelling on Graham terms: the Graham Number is $2.12 versus a $2.58 close on 2026-10-13, leaving a -21.70% margin of safety. The P/E is 13.58 and P/B is 2.48, which look fair to full, especially with ROCE of only 5.44% and a beta of 2.09. The proprietary ingredient may offer a niche, but I see no clear durable moat in these figures. I would want evidence that the profit drop is temporary and that pricing power is real before calling this a bargain.

In plain English: Niagen Bioscience makes healthy-aging supplements and ingredients, including a NAD+ product, and also works on pharmaceutical uses. The business has been profitable after a loss, but recent sales and profit have slipped, and the latest quarter was only barely profitable. At $2.58, the stock looks near its 52-week low and roughly fair to a bit expensive compared with its earnings and what it owns, so it is not an obvious bargain from the numbers given.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer